120 related articles for article (PubMed ID: 8461645)
1. Use of tumour marker immunoreactivity to identify primary site of metastatic cancer.
Gamble AR; Bell JA; Ronan JE; Pearson D; Ellis IO
BMJ; 1993 Jan; 306(6873):295-8. PubMed ID: 8461645
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site.
Brown RW; Campagna LB; Dunn JK; Cagle PT
Am J Clin Pathol; 1997 Jan; 107(1):12-9. PubMed ID: 8980361
[TBL] [Abstract][Full Text] [Related]
3. Tumour marker immunoreactivity in adenocarcinoma.
Ellis IO; Hitchcock A
J Clin Pathol; 1988 Oct; 41(10):1064-7. PubMed ID: 3192728
[TBL] [Abstract][Full Text] [Related]
4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
5. Specificity of colon specific antigen and colon ovarian tumour antigen.
Dorman AM; Chin D; Leader M
J Clin Pathol; 1992 Oct; 45(10):932-3. PubMed ID: 1385484
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody immunophenotyping of solitary cerebral metastases with unknown primary sites.
Clark WC; Nicoll JA; Coakham H
Br J Neurosurg; 1989; 3(5):591-5. PubMed ID: 2818851
[TBL] [Abstract][Full Text] [Related]
7. Intracytoplasmic lumina--a useful diagnostic feature of adenocarcinomas.
Quincey C; Raitt N; Bell J; Ellis IO
Histopathology; 1991 Jul; 19(1):83-7. PubMed ID: 1916690
[TBL] [Abstract][Full Text] [Related]
8. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
[TBL] [Abstract][Full Text] [Related]
9. Anti-Leu 7 immunoreactivity with human tumours: its value in the diagnosis of prostatic adenocarcinoma.
May EE; Perentes E
Histopathology; 1987 Mar; 11(3):295-304. PubMed ID: 2448219
[TBL] [Abstract][Full Text] [Related]
10. Disseminated prostatic carcinoma simulating primary lung cancer. Indications for immunodiagnostic studies.
Gentile PS; Carloss HW; Huang TY; Yam LT; Lam WK
Cancer; 1988 Aug; 62(4):711-5. PubMed ID: 2456142
[TBL] [Abstract][Full Text] [Related]
11. [An immunohistological study of metastatic adenocarcinoma of the lymph node: is it useful in diagnosing a primary tumor?].
Hamaya K; Doi K; Yoshizawa S; Motoi M
Gan No Rinsho; 1988 Nov; 34(14):1956-60. PubMed ID: 2462648
[TBL] [Abstract][Full Text] [Related]
12. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen.
Ernst CS; Atkinson B; Chianese D; Peters J; Perry M; Herlyn M; Koprowski H
Appl Pathol; 1986; 4(3):115-24. PubMed ID: 2885017
[TBL] [Abstract][Full Text] [Related]
13. Metastatic adenocarcinoma of an unknown primary site. A comparison of the relative contributions of morphology, minimal essential clinical data and CEA immunostaining status.
Sheahan K; O'Keane JC; Abramowitz A; Carlson JA; Burke B; Gottlieb LS; O'Brien MJ
Am J Clin Pathol; 1993 Jun; 99(6):729-35. PubMed ID: 8322709
[TBL] [Abstract][Full Text] [Related]
14. Metastatic adenocarcinoma of unknown primary origin.
Hammar SP
Hum Pathol; 1998 Dec; 29(12):1393-402. PubMed ID: 9865824
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice.
Ford TF; Butcher DN; Masters JR; Parkinson MC
Br J Urol; 1985 Feb; 57(1):50-5. PubMed ID: 2578846
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against carcinoembryonic antigen (CEA) discriminate between CEA produced by gastrointestinal tumors and CEA produced by other tumors.
Catane R; Ben Yoseff R; Livni N; Rosenmann E; Eshhar Z
Nat Immun Cell Growth Regul; 1990; 9(3):203-8. PubMed ID: 2196460
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
Afify AM; al-Khafaji BM
Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029
[TBL] [Abstract][Full Text] [Related]
18. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
19. Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity.
Thor A; Muraro R; Gorstein F; Ohuchi N; Viglione M; Szpak CA; Johnston WW; Schlom J
Cancer Res; 1987 Jan; 47(2):505-12. PubMed ID: 2431771
[TBL] [Abstract][Full Text] [Related]
20. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
